CoChat

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Abstract

Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products ( i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation–incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.0c00182

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Algar J., 1934, Proc. R. Ir. Acad., Sect. B, 42, 1

Cited by

See all 154

Metadata

Authors
Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., Eam, B., Young, N. P., Fish, S., Chen, J., Howard, H., Staunton, J., Molter, J., Clarine, J., Nevarez, A., Chiang, G. G., Appleman, J. R., Webster, K. R., & Reich, S. H.
Affiliations
  • Inception Therapeutics, 6175 Nancy Ridge Drive, San Diego, California 92121, United States
  • eFFECTOR Therapeutics (United States) (US)
  • Genentech (US)
  • Gossamer Bio (United States) (US)
  • WuXi AppTec (United States) (US)
  • Calporta Therapeutics, 11099 North Torrey Poines Rd., La Jolla, California 92037, United States
  • Casma Therapeutics (United States) (US)
  • Plexium, Inc., 11585 Sorrento Valley Rd., San Diego, California 92121, United States
  • Providence Portland Medical Center (US)
  • Escient Pharmaceuticals, 10578 Science Center Dr., San Diego, California 92121, United States
  • Primmune Therapeutics, 3210 Merryfield Row, San Diego, California 92121, United States
  • Frontier Medicines (United States) (US)
Corresponding author
Ernst, Justin T.
Venue
Journal of Medicinal Chemistry
Published
2020-05-29
Volume
63
Issue
11
Pages
5879-5955
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W3031081298
Cited by
150
References
41
Citations by year
2026: 20 · 2025: 26 · 2024: 29 · 2023: 24 · 2022: 17 · 2021: 26 · 2020: 8
FWCI
6.25
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
eIF4A, DEAD-box RNA helicase, eIF4F, cap-dependent translation, anticancer agents, ligand-based drug design, anticancer activity
MeSH terms
Animals, Benzofurans, Binding Sites, Breast Neoplasms, Female, Half-Life, Humans, Ligands, Mice, Nude, RNA, Messenger, Structure-Activity Relationship, Drug Design, Mutagenesis, Site-Directed, Protein Structure, Tertiary, Crystallography, X-Ray, Eukaryotic Initiation Factor-4A, Cell Line, Tumor, Mice, Rats, Molecular Dynamics Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. https://app.cochat.ai/papers/10.1021/acs.jmedchem.0c00182
The paper
Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., Eam, B., Young, N. P., Fish, S., Chen, J., Howard, H., Staunton, J., Molter, J., Clarine, J., Nevarez, A., . . . Reich, S. H. (2020). Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.0c00182

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.